Packages (Simulation)
Reagent Preparation
Image (I)
Image (II)
Certificate
Multiplex Assay Kit for Beta Catenin (β-catenin) ,etc. by FLIA (Flow Luminescence Immunoassay)
CTNNb1; bCat; b-Cat; CTNN-B1; Catenin Beta 1; Cadherin-Associated Protein
(Note: Up to 8-plex in one testing reaction)
- Product No.LMB021Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Sample TypeSerum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length3.5h
- Detection Range0.01-10ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.003 ng/mL.
- DownloadInstruction Manual
- UOM 8Plex 7Plex 6Plex 5Plex 4Plex 3Plex 2Plex1Plex
- FOB
US$ 415
US$ 431
US$ 455
US$ 487
US$ 519
US$ 567
US$ 638
Result
For more details, please contact local distributors! US$ 798 Add to Price Calculator
Specificity
This assay has high sensitivity and excellent specificity for detection of Beta Catenin (β-catenin) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Beta Catenin (β-catenin) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Beta Catenin (β-catenin) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Beta Catenin (β-catenin) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 79-96 | 83 |
EDTA plasma(n=5) | 91-98 | 95 |
heparin plasma(n=5) | 81-102 | 84 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Beta Catenin (β-catenin) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Beta Catenin (β-catenin) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Beta Catenin (β-catenin) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 96-103% | 85-93% | 81-104% | 93-101% |
EDTA plasma(n=5) | 81-88% | 90-98% | 78-93% | 95-105% |
heparin plasma(n=5) | 81-105% | 87-104% | 79-98% | 89-97% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
96-well plate | 1 | Plate sealer for 96 wells | 4 |
Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
Pre-Mixed Magnetic beads (22#:β-catenin) | 1 | Analysis buffer | 1×20mL |
Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
GIVEAWAYS
INCREMENT SERVICES
Magazine | Citations |
Clinica Chimica Acta | Versican and its associated molecules: Potential diagnostic markers for multiple myeloma Pubmed:25623955 |
Journal of Bone and Mineral Research | Adverse effects of osteocytic constitutive activation of ?-catenin on bone strength and bone growth Pubmed:25639729 |
Am J Transl Res | Role of SDF-1 and Wnt signaling pathway in the myocardial fibrosis of hypertensive rats PubMed: 26396666 |
Scientific Reports | Is there an association between enhanced choline and β-catenin pathway in breast cancer? A pilot study by MR Spectroscopy and ELISA. pubmed:28533512 |
Life Sciences | Hepatoprotective effect of hesperidin in hepatocellular carcinoma: Involvement of Wnt signaling pathways. pubmed:28754618 |
Scientific Reports | Is there an association between enhanced choline and β-catenin pathway in breast cancer? A pilot study by MR Spectroscopy and ELISA Pubmed: 28533512 |
The Showa University Journal of Medical Sciences | Eribulin Treatment Induces High Expression of miR-195 and Inactivates the Wnt/β-catenin Signaling Pathway in Triple-negative Breast Cancer Doi: 10.15369/sujms.30.359 |
Advances in Medical Sciences | Urinary procollagen III aminoterminal propeptide and β-catenin–New diagnostic biomarkers in solitary functioning kidney? Pubmed: 30738287 |
Biomed Pharmacother | Silence of FAM83H-AS1 promotes chemosensitivity of gastric cancer through Wnt/β-catenin signaling pathway Pubmed: 32028241 |
Journal of Cosmetic Dermatology | Novel complex of cosmetic ingredients with promising action in preventing hair loss and follicular aging through mechanism involving enrichment of WNT/signaling … Pubmed: 33179848 |
Nutrients | Hydroxytyrosol as a Promising Ally in the Treatment of Fibromyalgia Pubmed: 32784915 |
Oncotarget | Amalgamation of PI3K and EZH2 blockade synergistically regulates invasion and angiogenesis: combination therapy for glioblastoma multiforme 33473259 |
Cytokine | QNZ alleviated hepatocellular carcinoma by targeting inflammatory pathways in a rat model 34564023 |